What is it about?
There are more than 145 targets in the pipeline of PD therapeutics at this time yet we lack patient centric objective and sensitive measures that capture the lived experience of people living with Parkinson's. Digital Health Technologies hold promise as tools for use in drug development.
Featured Image
Why is it important?
This manuscript outlines how collaborations can effectively align with regulatory agencies early and often to efficiently advance tools forward that are aligned with the voice of patients.
Perspectives
\My overall vision is that the world will recognize that Parkinson's is a hidden pandemic and deserves the same sense of urgency we are witnessing around the globe in response to COVID-19.
Diane Stephenson
Critical Path Institute
Read the Original
This page is a summary of: Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science, Digital Biomarkers, November 2020, Karger Publishers,
DOI: 10.1159/000512500.
You can read the full text:
Contributors
The following have contributed to this page
